Metformin as an Adjunctive Therapy for the Treatment of Metastatic Colorectal Cancer Patients Undergoing FOLFIRI Plus Target Therapy
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
• Aged between 20 and 90 years old
• Patients diagnosed with metastatic colorectal cancer who is going to receive FOLFIRI chemotherapy
• Female must not be planning to become pregnant or breastfeeding, and not pregnant at any point during treatment. (Contraception is required to participate in this trial)
• Those without major physiological diseases (example of major cardiovascular disease is acute myocardial infarction; example of major cerebrovascular disease is acute stroke, malignant hypertension, acute kidney failure, acute liver failure)
• Those who are not allergic to the relevant drugs required for the test
• Those who can follow the doctor's order to take the medicine
• Subjects must be willing to sign the consent form
• Blood sugar level above 80 mg/dL